Search Results - "CARLOMAGNO, Francesca"

NCOA4-mediated ferritinophagy in macrophages is crucial to sustain erythropoiesis in mice by Nai, Antonella, Lidonnici, Maria Rosa, Federico, Giorgia, Pettinato, Mariateresa, Olivari, Violante, Carrillo, Federica, Geninatti Crich, Simonetta, Ferrari, Giuliana, Camaschella, Clara, Silvestri, Laura, Carlomagno, Francesca

“…Nuclear receptor coactivator 4 (NCOA4) promotes ferritin degradation and Ncoa4-ko mice in a C57BL/6 background show microcytosis and mild anemia, aggravated by…”
Get full text

NCOA4 Deficiency Impairs Systemic Iron Homeostasis by Bellelli, Roberto, Federico, Giorgia, Matte’, Alessandro, Colecchia, David, Iolascon, Achille, Chiariello, Mario, Santoro, Massimo, De Franceschi, Lucia, Carlomagno, Francesca

“…The cargo receptor NCOA4 mediates autophagic ferritin degradation. Here we show that NCOA4 deficiency in a knockout mouse model causes iron accumulation in the…”
Get full text

Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases by Moccia, Marialuisa, Yang, Donglin, Lakkaniga, Naga Rajiv, Frett, Brendan, McConnell, Nicholas, Zhang, Lingtian, Brescia, Annalisa, Federico, Giorgia, Zhang, Lingzhi, Salerno, Paolo, Santoro, Massimo, Li, Hong-yu, Carlomagno, Francesca

“…We have recently described Pz-1, a benzimidazole-based type-2 RET and VEGFR2 inhibitor. Based on a kinome scan, here we show that Pz-1 is also a potent (IC 50 …”
Get full text

Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology by Moccia, Marialuisa, Frett, Brendan, Zhang, Lingtian, Lakkaniga, Naga Rajiv, Briggs, David C, Chauhan, Rakhee, Brescia, Annalisa, Federico, Giorgia, Yan, Wei, Santoro, Massimo, McDonald, Neil Q, Li, Hong-yu, Carlomagno, Francesca

“…RET receptor tyrosine kinase is a driver oncogene in human cancer. We recently identified the clinical drug candidate Pz-1, which targets RET and VEGFR2. A key…”
Get full text

Tamoxifen erythroid toxicity revealed by studying the role of nuclear receptor co-activator 4 in erythropoiesis by Nai, Antonella, Pettinato, Mariateresa, Federico, Giorgia, Olivari, Violante, Carlomagno, Francesca, Silvestri, Laura

Get full text

Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology by Frett, Brendan, Carlomagno, Francesca, Moccia, Maria Luisa, Brescia, Annalisa, Federico, Giorgia, De Falco, Valentina, Admire, Brittany, Chen, Zhongzhu, Qi, Wenqing, Santoro, Massimo, Li, Hong-yu

“…Oncogenic conversion of the RET (rearranged during transfection) tyrosine kinase is associated with several cancers. A fragment‐based chemical screen led to…”
Get full text

NCOA4 Transcriptional Coactivator Inhibits Activation of DNA Replication Origins by Bellelli, Roberto, Castellone, Maria Domenica, Guida, Teresa, Limongello, Roberto, Dathan, Nina Alayne, Merolla, Francesco, Cirafici, Anna Maria, Affuso, Andrea, Masai, Hisao, Costanzo, Vincenzo, Grieco, Domenico, Fusco, Alfredo, Santoro, Massimo, Carlomagno, Francesca

“…NCOA4 is a transcriptional coactivator of nuclear hormone receptors that undergoes gene rearrangement in human cancer. By combining studies in Xenopus laevis…”
Get full text

Iron and Ferritin Modulate MHC Class I Expression and NK Cell Recognition by Sottile, Rosa, Federico, Giorgia, Garofalo, Cinzia, Tallerico, Rossana, Faniello, Maria Concetta, Quaresima, Barbara, Cristiani, Costanza Maria, Di Sanzo, Maddalena, Cuda, Gianni, Ventura, Valeria, Wagner, Arnika Kathleen, Contrò, Gianluca, Perrotti, Nicola, Gulletta, Elio, Ferrone, Soldano, Kärre, Klas, Costanzo, Francesco Saverio, Carlomagno, Francesca, Carbone, Ennio

“…The ability of pathogens to sequester iron from their host cells and proteins affects their virulence. Moreover, iron is required for various innate host…”
Get full text

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors by CARLOMAGNO, Francesca, GUIDA, Teresa, ANAGANTI, Suresh, VECCHIO, Giancarlo, FUSCO, Alfredo, RYAN, Anderson J, BILLAUD, Marc, SANTORO, Massimo

“…We have recently demonstrated that the pyrazolopyrimidines PP1 and PP2 and the 4-anilinoquinazoline ZD6474 display a strong inhibitory activity (IC(50)< or…”
Get full text

Antitumor Effects of ZD6474, a Small Molecule Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, with Additional Activity against Epidermal Growth Factor Receptor Tyrosine Kinase by CIARDIELLO, Fortunato, CAPUTO, Rosa, TORTORA, Giampaolo, DAMIANO, Vincenzo, CAPUTO, Roberta, TROIANI, Teresa, VITAGLIANO, Donatella, CARLOMAGNO, Francesca, VENEZIANI, Bianca Maria, FONTANINI, Gabriella, BIANCO, A. Raffaele

“…Purpose: Vascular endothelial growth factor (VEGF) is a major mitogen for endothelial cells and enhances vascular permeability. Enhanced VEGF secretion is…”
Get full text

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase by Moccia, Marialuisa, Liu, Qingsong, Guida, Teresa, Federico, Giorgia, Brescia, Annalisa, Zhao, Zheng, Choi, Hwan Geun, Deng, Xianming, Tan, Li, Wang, Jinhua, Billaud, Marc, Gray, Nathanael S, Carlomagno, Francesca, Santoro, Massimo

“…Oncogenic mutation of the RET receptor tyrosine kinase is observed in several human malignancies. Here, we describe three novel type II RET tyrosine kinase…”
Get full text

BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma by SALVATORE, Giuliana, DE FALCO, Valentina, SALERNO, Paolo, NAPPI, Tito Claudio, PEPE, Stefano, TRONCONE, Giancarlo, CARLOMAGNO, Francesca, MELILLO, Rosa Marina, WILHELM, Scott M, SANTORO, Massimo

“…Purpose: Oncogenic conversion of BRAF occurs in ∼44% of papillary thyroid carcinomas and 24% of anaplastic thyroid carcinomas. In papillary thyroid carcinomas,…”
Get full text

Identification of Polo-like Kinase 1 as a Potential Therapeutic Target in Anaplastic Thyroid Carcinoma by CLAUDIO NAPPI, Tito, SALERNO, Paolo, ZITZELSBERGER, Horst, CARLOMAGNO, Francesca, SALVATORE, Giuliana, SANTORO, Massimo

“…Anaplastic thyroid carcinoma (ATC) is one of the most aggressive and chemoresistant cancers. The serine/threonine kinase Polo-like kinase 1 (PLK1), a key…”
Get full text

Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth Factor Receptor β Gatekeeper Mutants by GUIDA, Teresa, ANAGANTI, Suresh, PROVITERA, Livia, GEDRICH, Richard, SULLIVAN, Elizabeth, WILHELM, Scott M, SANTORO, Massimo, CARLOMAGNO, Francesca

“…Purpose: Targeting of KIT and platelet-derived growth factor receptor (PDGFR) tyrosine kinases by imatinib is an effective anticancer strategy. However,…”
Get full text

Structure prediction and validation of the ERK8 kinase domain by Strambi, Angela, Mori, Mattia, Rossi, Matteo, Colecchia, David, Manetti, Fabrizio, Carlomagno, Francesca, Botta, Maurizio, Chiariello, Mario

“…Extracellular signal-regulated kinase 8 (ERK8) has been already implicated in cell transformation and in the protection of genomic integrity and, therefore,…”
Get full text

Functional expression of the CXCR4 chemokine receptor is induced by RET PTC oncogenes and is a common event in human papillary thyroid carcinomas by CASTELLONE, Maria D, GUARINO, Valentina, FUSCO, Alfredo, SANTORO, Massimo, MELILLO, Rosa Marina, DE FALCO, Valentina, CARLOMAGNO, Francesca, BASOLO, Fulvio, FAVIANA, Pinuccia, KRUHOFFER, Mogens, ORNTOFT, Torben, RUSSELL, John P, ROTHSTEIN, Jay L

“…To identify genes involved in the transformation of thyroid follicular cells, we explored, using DNA oligonucleotide microarrays, the transcriptional response…”
Get full text

The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells by Vitagliano, Donata, De Falco, Valentina, Tamburrino, Anna, Coluzzi, Sabrina, Troncone, Giancarlo, Chiappetta, Gennaro, Ciardiello, Fortunato, Tortora, Giampaolo, Fagin, James A, Ryan, Anderson J, Carlomagno, Francesca, Santoro, Massimo

“…Oncogenic conversion of the RET tyrosine kinase is a frequent feature of medullary thyroid carcinoma (MTC). ZD6474 (vandetanib) is an ATP-competitive inhibitor…”
Get full text

Functional characterization of a novel FGFR1OP-RET rearrangement in hematopoietic malignancies by Bossi, Daniela, Carlomagno, Francesca, Pallavicini, Isabella, Pruneri, Giancarlo, Trubia, Maurizio, Raviele, Paola Rafaniello, Marinelli, Alessandra, Anaganti, Suresh, Cox, Maria Christina, Viale, Giuseppe, Santoro, Massimo, Di Fiore, Pier Paolo, Minucci, Saverio

“…The RET (REarranged during Transfection) receptor tyrosine kinase is targeted by oncogenic rearrangements in thyroid and lung adenocarcinoma. Recently, a RET…”
Get full text

Molecular Mechanisms of RET Activation in Human Cancer by SANTORO, MASSIMO, MELILLO, ROSA MARINA, CARLOMAGNO, FRANCESCA, FUSCO, ALFREDO, VECCHIO, GIANCARLO

“…: Mutations that produce oncogenes with dominant gain of function target receptor protein tyrosine kinases (PTKs) in cancer and confer uncontrolled…”
Get full text

The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins by IERVOLINO, Angela, IULIANO, Rodolfo, TRAPASSO, Francesco, VIGLIETTO, Giuseppe, MELILLO, Rosa Marina, CARLOMAGNO, Francesca, SANTORO, Massimo, FUSCO, Alfredo

“…Thyroid cancer is frequently associated with the oncogenic conversion of the RET receptor tyrosine kinase. RET gene rearrangements, which lead to the…”
Get full text